Addition of Tiragolumab Fails to Improve Front-Line Outcomes in Advanced Hepatocellular Carcinoma
Richard Finn, MD, UCLA Health, Los Angeles, California, discusses results from the phase 3 IMbrave152/SKYSCRAPER-14 study evaluating tiragolumab in combination with atezolizumab and bevacizumab versus atezolizumab, bevacizumab, and placebo in patients with advanced hepatocellular carcinoma.
The study did not meet its primary end points for progression-free or overall survival with efficacy outcomes similar between the triplet and doublet arms however, the trial reinforces the strong benchmark performance of atezolizumab plus bevacizumab and provides important insights for future immunotherapy development in liver cancer.
These results were presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.
Source:
Finn R, Singal AG, Cheng AL, et al. IMbrave152/SKYSCRAPER-14: a phase 3 study of first-line tiragolumab (tira) + atezolizumab (atezo) + bevacizumab (bev) vs placebo (pbo) + atezo + bev for patients (pts) with untreated locally advanced or metastatic hepatocellular carcinoma (HCC). Presented at the 2025 ESMO Congress. October 17-21, 2025; Berlin, Germany. LBA50
